Back

Cardiovascular events in CML patients treated with nilotinib: validation of the HFA-ICOS baseline risk score

30 August 2024 (13:15 - 13:30)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology in practice Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Maria Sol Andres

Royal Brompton Hospital, London (United Kingdom of Great Britain & Northern Ireland)

2 More presentations in this session

Presentation thumbnail
The safety of standardized management of suspected cardiovascular immune-related events in patients treated by immunecheckpoints inhibitors
Doctor F. Cribari (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Unraveling immune checkpoint inhibitors effects on atherosclerosis: mechanisms and preventive approaches
Doctor I. Nardi Agmon (Ramat Gan, IL)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology in practice
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular and non-cardiovascular adverse events in patients with hematologic malignacies treated with BTK inhibitors: a real-world analysis
thumbnail
Congress Presentation
Advances in myeloproliferative neoplasms treatment
thumbnail
Congress Presentation
Nilotinib-associated coronary artery disease in patient with chronic myeloid leukaemia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources